| RA | Other arthritides1 | P value, RA vs other arthritides | Healthy controls | P value, RA vs healthy controls |
---|---|---|---|---|---|
n = 157 | n = 284 |  | n = 193 |  | |
Clinical features | |||||
 Age, mean (SD) | 59 (14) | 56 (17) | 0.07 | 50 (16) | < 0.001 |
 Female, n (%) | 109 (69) | 158 (56) | 0.005 | 136 (71) | 0.83 |
 BMI, mean (SD) | 26 (5) | 27 (4) | 0.52 | 25 (4) | 0.003 |
Symptom duration, in weeks, median (IQR) | 10 (5–28) | 8 (4–26) | 0.13 | NA | NA |
Swollen joint count, median (IQR) | 7 (2–11) | 2 (1–4) | < 0.001 | NA | NA |
CRP, mg/L, median (IQR) | 9 (4–26) | 6 (3–16) | < 0.001 | NA | NA |
RF positive, n (%) | 106 (68) | 51 (18) | < 0.001 | NA | NA |
ACPA positive, n (%) | 87 (59) | 69 (25) | < 0.001 | NA | NA |
MRI features | |||||
 Mean number of lesions per patient, n (SD) | |||||
  Intermetatarsal bursitis | 1.6 (1.4) | 0.6 (1.0) | < 0.001 | 0.2 (0.7) | < 0.001 |
  Submetatarsal bursitis | 0.4 (0.8) | 0.07 (0.3) | < 0.001 | 0.04 (0.2) | < 0.001 |
  Morton’s neuroma | 0.4 (0.6) | 0.06 (0.3) | < 0.001 | 0.03 (0.2) | < 0.001 |
  Diffuse submetatarsal alterations | 0.5 (1.1) | 0.3 (0.9) | 0.068 | 0.3 (0.9) | 0.092 |